TNF -α modulating benzimidazoles
US9550737B2 · kind B2 · utility
2Cited by
5References
10Claims
0Family size
Assignee
Inventors
- Daniel Christopher Brookings
- Mark Daniel Calmiano
- Ellen Olivia Gallimore
- Helen Tracey Horsley
- Martin Clive Hutchings
- James A. Johnson
- Boris Kroeplien
- Fabien Claude Lecomte
- Martin Alexander Lowe
- Timothy John Norman
- John Robert Porter
- Joanna Rachel Quincey
- James Thomas Reuberson
- Matthew Duncan Selby
- Michael Alan Shaw
- Zhaoning Zhu
- Anne Marie Foley
Key dates
| Filing date | Jun 11, 2013 |
| Grant date | Jan 24, 2017 |
| Priority date | — |
| Expiry date | Jun 11, 2033 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D491/107
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A series of benzimidazole derivatives, being potent modulators of human TNFα activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.